Condition: Glioma, Astrocytic · Sponsor: National University Hospital, Singapore
This is an interventional, non-randomized, single site study. Brain tumor samples will be collected from patients for organoids generation and subject to panel drugs screening and QPOP analysis to derive the optimal drug combinations for treatment at the time of first high grade astrocytic glioma recurrence. The investigators hypothesize that patient-derived organoids (PDOs) mimic the biological characteristics of high grade astrocytic gliomas and serve as an ideal platform for the evaluation of drug sensitivities, accurately reflecting the patient's therapeutic response to the drugs.
This description comes directly from the study's public registry record.
Andrea Wong · +65 6908 2222 · andrea_la_wong@nuhs.edu.sg
Always discuss trial participation with your own doctor first.
| Department of Hematology-Oncology, National University Hospital | Singapore, Singapore | Recruiting |
| Ng Teng Fong General Hospital | Singapore, Singapore | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05532397